chr15-55450341-C-T
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_130810.4(DNAAF4):c.664G>A(p.Glu222Lys) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000279 in 1,611,604 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 14/20 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★).
Frequency
Consequence
NM_130810.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
DNAAF4 | NM_130810.4 | c.664G>A | p.Glu222Lys | missense_variant | 6/10 | ENST00000321149.7 | NP_570722.2 | |
DNAAF4-CCPG1 | NR_037923.1 | n.919G>A | non_coding_transcript_exon_variant | 5/16 | ||||
DNAAF4 | NM_001033560.2 | c.664G>A | p.Glu222Lys | missense_variant | 6/9 | NP_001028732.1 | ||
DNAAF4 | NM_001033559.3 | c.664G>A | p.Glu222Lys | missense_variant | 6/9 | NP_001028731.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
DNAAF4 | ENST00000321149.7 | c.664G>A | p.Glu222Lys | missense_variant | 6/10 | 1 | NM_130810.4 | ENSP00000323275 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000263 AC: 4AN: 152120Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.000161 AC: 40AN: 248300Hom.: 0 AF XY: 0.000142 AC XY: 19AN XY: 134058
GnomAD4 exome AF: 0.0000281 AC: 41AN: 1459484Hom.: 0 Cov.: 30 AF XY: 0.0000289 AC XY: 21AN XY: 725826
GnomAD4 genome AF: 0.0000263 AC: 4AN: 152120Hom.: 0 Cov.: 33 AF XY: 0.0000538 AC XY: 4AN XY: 74316
ClinVar
Submissions by phenotype
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Apr 01, 2024 | The c.664G>A (p.E222K) alteration is located in exon 6 (coding exon 5) of the DYX1C1 gene. This alteration results from a G to A substitution at nucleotide position 664, causing the glutamic acid (E) at amino acid position 222 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
not provided Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 22, 2022 | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt DYX1C1 protein function. ClinVar contains an entry for this variant (Variation ID: 575687). This variant has not been reported in the literature in individuals affected with DYX1C1-related conditions. This variant is present in population databases (rs763879829, gnomAD 0.1%). This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 222 of the DYX1C1 protein (p.Glu222Lys). - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at